Responses
Late-Breaking Abstracts
Clinical Trial in Progress
1527 ENB-003, an ETBR antagonist, in combination with pembrolizumab, shows promise in microsatellite stable platinum refractory/resistant ovarian cancer: data from the ENBOLDEN-101 phase 1B study
Compose a Response to This Article
Other responses
No responses have been published for this article.
